• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

协和研究：一项关于新型药物与传统放疗联合用于非小细胞肺癌的I期平台研究。

CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer.

作者信息

Walls Gerard M, Oughton Jamie B, Chalmers Anthony J, Brown Sarah, Collinson Fiona, Forster Martin D, Franks Kevin N, Gilbert Alexandra, Hanna Gerard G, Hannaway Nicola, Harrow Stephen, Haswell Tom, Hiley Crispin T, Hinsley Samantha, Krebs Matthew, Murden Geraldine, Phillip Rachel, Ryan Anderson J, Salem Ahmed, Sebag-Montefoire David, Shaw Paul, Twelves Chris J, Walker Katrina, Young Robin J, Faivre-Finn Corinne, Greystoke Alastair

机构信息

Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Northern Ireland, UK.

Leeds Institute of Clinical Trials Research, University of Leeds, England, UK.

出版信息

Clin Transl Radiat Oncol. 2020 Sep 22;25:61-66. doi: 10.1016/j.ctro.2020.09.006. eCollection 2020 Nov.

DOI:10.1016/j.ctro.2020.09.006
PMID:33072895
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7548952/
Abstract

Lung cancer is the leading cause of cancer mortality worldwide and most patients are unsuitable for 'gold standard' treatment, which is concurrent chemoradiotherapy. CONCORDE is a platform study seeking to establish the toxicity profiles of multiple novel radiosensitisers targeting DNA repair proteins in patients treated with sequential chemoradiotherapy. Time-to-event continual reassessment will facilitate efficient dose-finding.

摘要

肺癌是全球癌症死亡的主要原因，大多数患者不适合采用“金标准”治疗，即同步放化疗。CONCORDE是一项平台研究，旨在确定在接受序贯放化疗的患者中，多种针对DNA修复蛋白的新型放射增敏剂的毒性特征。事件发生时间的连续重新评估将有助于高效的剂量探索。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af70/7548952/6ab2257389aa/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af70/7548952/6ab2257389aa/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af70/7548952/6ab2257389aa/gr1.jpg

相似文献

1
CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer.协和研究：一项关于新型药物与传统放疗联合用于非小细胞肺癌的I期平台研究。
Clin Transl Radiat Oncol. 2020 Sep 22;25:61-66. doi: 10.1016/j.ctro.2020.09.006. eCollection 2020 Nov.
2
Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib.三项平行 I 期试验研究方案，联合根治性放疗和 PARP 抑制剂奥拉帕利。
BMC Cancer. 2019 Sep 10;19(1):901. doi: 10.1186/s12885-019-6121-3.
3
Primary lung tumour stereotactic body radiotherapy followed by concurrent mediastinal chemoradiotherapy and adjuvant immunotherapy for locally advanced non-small-cell lung cancer: a multicentre, single-arm, phase 2 trial.原发性肺肿瘤立体定向体部放疗联合同步纵隔放化疗及辅助免疫治疗用于局部晚期非小细胞肺癌：一项多中心、单臂、2期试验
Lancet Oncol. 2025 Jan;26(1):85-97. doi: 10.1016/S1470-2045(24)00573-4. Epub 2024 Nov 29.
4
Olaparib maintenance versus placebo monotherapy in patients with advanced non-small cell lung cancer (PIN): A multicentre, randomised, controlled, phase 2 trial.奥拉帕利维持治疗对比安慰剂单药治疗晚期非小细胞肺癌患者（PIN）：一项多中心、随机、对照、2期试验。
EClinicalMedicine. 2022 Aug 11;52:101595. doi: 10.1016/j.eclinm.2022.101595. eCollection 2022 Oct.
5
Stereotactic ablative radiotherapy after concomitant chemoradiotherapy in non-small cell lung cancer: A TITE-CRM phase 1 trial.同期放化疗后立体定向消融放疗治疗非小细胞肺癌：TITE-CRM 阶段 1 试验。
Radiother Oncol. 2018 May;127(2):239-245. doi: 10.1016/j.radonc.2018.03.024. Epub 2018 Apr 9.
6
Implementation of the Time-to-Event Continuous Reassessment Method Design in a Phase I Platform Trial Testing Novel Radiotherapy-Drug Combinations-CONCORDE.在一项测试新型放疗-药物组合的 I 期平台试验中实施事件时间连续评估方法设计 - CONCORDE。
JCO Precis Oncol. 2022 Nov;6:e2200133. doi: 10.1200/PO.22.00133.
7
Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial.基于影像学的局部晚期非小细胞肺癌放化疗靶区缩小（PET-Plan）：一项多中心、开放标签、随机、对照试验。
Lancet Oncol. 2020 Apr;21(4):581-592. doi: 10.1016/S1470-2045(20)30013-9. Epub 2020 Mar 12.
8
Ataxia-telangiectasia mutated and ataxia telangiectasia and Rad3-related kinases as therapeutic targets and stratification indicators for prostate cancer.共济失调毛细血管扩张突变基因和共济失调毛细血管扩张症和 Rad3 相关激酶作为前列腺癌的治疗靶点和分层指标。
Int J Biochem Cell Biol. 2022 Jun;147:106230. doi: 10.1016/j.biocel.2022.106230. Epub 2022 May 21.
9
Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.表皮生长因子受体突变（EGFR）检测对晚期非小细胞肺癌患者使用表皮生长因子受体靶向酪氨酸激酶抑制剂（TKI）药物疗效的预测：一项循证分析
Ont Health Technol Assess Ser. 2010;10(24):1-48. Epub 2010 Dec 1.
10
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial.舒格利单抗联合同步或序贯放化疗对比安慰剂用于中国局部晚期、不可切除、III 期非小细胞肺癌患者的 GEMSTONE-301 研究：一项随机、双盲、多中心、III 期临床研究的期中分析结果
Lancet Oncol. 2022 Feb;23(2):209-219. doi: 10.1016/S1470-2045(21)00630-6. Epub 2022 Jan 14.

引用本文的文献

1
Tumor control and immune activation through palliative irradiation and ATR inhibition, PATRIOT Part C: a phase Ib trial.通过姑息性放疗和 ATR 抑制实现肿瘤控制与免疫激活，PATRIOT 研究 C 部分：一项 Ib 期试验
Nat Commun. 2025 Aug 1;16(1):7064. doi: 10.1038/s41467-025-62249-0.
2
Should Radiation Dose Be Personalized in Patients With Localized NSCLC and Actionable Genetic Alterations? Insight From a Multicenter Real-World Study.局限性非小细胞肺癌且有可操作基因改变的患者，放射剂量是否应个体化？一项多中心真实世界研究的见解。
JTO Clin Res Rep. 2024 Nov 22;6(4):100774. doi: 10.1016/j.jtocrr.2024.100774. eCollection 2025 Apr.
3

本文引用的文献

1
DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer.癌症放疗增敏的 DNA 损伤反应信号通路和靶点。
Signal Transduct Target Ther. 2020 May 1;5(1):60. doi: 10.1038/s41392-020-0150-x.
2
Olaparib for Metastatic Castration-Resistant Prostate Cancer.奥拉帕利治疗转移性去势抵抗性前列腺癌。
N Engl J Med. 2020 May 28;382(22):2091-2102. doi: 10.1056/NEJMoa1911440. Epub 2020 Apr 28.
3
The UK at the Forefront of Innovative Drug-Radiotherapy Combination Clinical Trials: Introducing the CONCORDE Platform.
Cancer Vulnerabilities Through Targeting the ATR/Chk1 and ATM/Chk2 Axes in the Context of DNA Damage.
在DNA损伤背景下通过靶向ATR/Chk1和ATM/Chk2轴发现癌症脆弱性
Cells. 2025 May 20;14(10):748. doi: 10.3390/cells14100748.
4
Circulating tumor DNA kinetics: A future tool for radiation therapy personalization in lung cancer?循环肿瘤DNA动力学：肺癌放疗个体化的未来工具？
J Liq Biopsy. 2024 Jun 21;6:100160. doi: 10.1016/j.jlb.2024.100160. eCollection 2024 Dec.
5
The Development of ATM Inhibitors in Cancer Therapy.ATM抑制剂在癌症治疗中的发展
Target Oncol. 2025 Mar;20(2):281-297. doi: 10.1007/s11523-025-01136-6. Epub 2025 Mar 1.
6
Exploring Consent to Use Real-World Data in Lung Cancer Radiotherapy: Decision of a Citizens' Jury for an 'Informed Opt-Out' Approach.探索肺癌放疗中使用真实世界数据的同意问题：公民陪审团对“知情选择退出”方法的决定
Health Care Anal. 2025 Jun;33(2):192-213. doi: 10.1007/s10728-025-00510-9. Epub 2025 Feb 10.
7
Cardiotoxicity following thoracic radiotherapy for lung cancer.肺癌胸部放疗后的心脏毒性
Br J Cancer. 2025 Mar;132(4):311-325. doi: 10.1038/s41416-024-02888-0. Epub 2024 Nov 6.
8
Challenges and opportunities for early phase clinical trials of novel drug-radiotherapy combinations: recommendations from NRG Oncology, the American Society for Radiation Oncology (ASTRO), the American College of Radiology (ACR), the Sarah Cannon Research Institute, and the American College of Radiation Oncology (ACRO).新型药物联合放疗的早期临床试验面临的挑战与机遇：美国肿瘤放射治疗协作组（NRG Oncology）、美国放射肿瘤学会（ASTRO）、美国放射学院（ACR）、Sarah Cannon 研究所以及美国放射肿瘤学会（ACRO）的建议。
Lancet Oncol. 2024 Oct;25(10):e489-e500. doi: 10.1016/S1470-2045(24)00264-X.
9
Radiotherapy with S-1 for the treatment of esophageal squamous cell carcinoma 75 years or older.S-1 放疗治疗 75 岁及以上食管鳞癌。
Radiat Oncol. 2024 Aug 29;19(1):112. doi: 10.1186/s13014-024-02509-3.
10
PTEN Depletion Increases Radiosensitivity in Response to Ataxia Telangiectasia-Related-3 (ATR) Inhibition in Non-Small Cell Lung Cancer (NSCLC).PTEN 耗竭增加了非小细胞肺癌 (NSCLC) 对共济失调毛细血管扩张症相关激酶 3 (ATR) 抑制的放射敏感性。
Int J Mol Sci. 2024 Jul 17;25(14):7817. doi: 10.3390/ijms25147817.
英国处于创新药物-放射治疗联合临床试验的前沿：介绍协和平台。
Clin Oncol (R Coll Radiol). 2020 Jun;32(6):358-362. doi: 10.1016/j.clon.2020.02.003. Epub 2020 Feb 24.
4
Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial.随机试验中 CT 容积筛查降低肺癌死亡率
N Engl J Med. 2020 Feb 6;382(6):503-513. doi: 10.1056/NEJMoa1911793. Epub 2020 Jan 29.
5
Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer.NRG肿瘤学RTOG 0617的长期结果：不可切除的III期非小细胞肺癌采用标准剂量与高剂量放化疗联合或不联合西妥昔单抗的疗效对比
J Clin Oncol. 2020 Mar 1;38(7):706-714. doi: 10.1200/JCO.19.01162. Epub 2019 Dec 16.
6
Long-Term Results from the IDEAL-CRT Phase 1/2 Trial of Isotoxically Dose-Escalated Radiation Therapy and Concurrent Chemotherapy for Stage II/III Non-small Cell Lung Cancer.IDeal-CRT 阶段 1/2 试验：等毒性剂量递增放疗联合同期化疗治疗 II/III 期非小细胞肺癌的长期结果。
Int J Radiat Oncol Biol Phys. 2020 Mar 15;106(4):733-742. doi: 10.1016/j.ijrobp.2019.11.397. Epub 2019 Dec 3.
7
Altering DNA Repair to Improve Radiation Therapy: Specific and Multiple Pathway Targeting.改变DNA修复以改善放射治疗：特异性和多途径靶向
Front Oncol. 2019 Oct 10;9:1009. doi: 10.3389/fonc.2019.01009. eCollection 2019.
8
Stage III Non-small Cell Lung Cancer Management in England.英格兰 III 期非小细胞肺癌的管理。
Clin Oncol (R Coll Radiol). 2019 Oct;31(10):688-696. doi: 10.1016/j.clon.2019.07.020.
9
Remarkable response to a novel ATR inhibitor in a patient with poorly differentiated neuroendocrine carcinoma.一名低分化神经内分泌癌患者对新型 ATR 抑制剂产生显著反应。
Cancer Treat Res Commun. 2018;16:9-12. doi: 10.1016/j.ctarc.2018.04.001. Epub 2018 Apr 23.
10
Clinical Development of Novel Drug-Radiotherapy Combinations.新型药物-放疗联合的临床开发。
Clin Cancer Res. 2019 Mar 1;25(5):1455-1461. doi: 10.1158/1078-0432.CCR-18-2466. Epub 2018 Nov 29.